AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02157350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Description: Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
Study NCT03991091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinuation of oxytocin administration
Description: Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
Study NCT03991091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation of oxytocin administration
Description: continuation of oxytocin administration
Study NCT00559585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous (SC) Abatacept
Description: Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
Study NCT00559585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Abatacept
Description: Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions
Study NCT02746666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist's behavioral intervention
Description: Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
Study NCT01536236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANS Eon™ Implantable Pulse Generator (Permanent Implant)
Description: Appropriate programming based on subject's preference of programs.
Study NCT01536236 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ANS Eon™ Implantable Pulse Generator (Permanent Implant)
Description: Appropriate programming based on subject's preference of programs.
Study NCT01536236 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03886792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triggered reinforcement
Description: This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
Study NCT03886792 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social interaction
Description: This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
Study NCT04147325 — intervention group
Intervention type: DRUG
Intervention: Antiretroviral Therapy
Description: ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
Study NCT03187171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Fusion
Description: ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
Study NCT03187171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cohere PEEK Fusion Group
Description: Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175mg/m2
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 75mg/m2
Study NCT03691090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin 75mg/m2
Study NCT01438151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
Study NCT00769860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimoclomol
Description: Arimoclomol 100 mg TID for 4 months
Study NCT00769860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 4 months
Study NCT02812901 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery scheduled in the morning
Description: cardiac surgery scheduled in the morning
Study NCT02812901 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery scheduled in the afternoon
Description: cardiac surgery scheduled in the afternoon
Study NCT02173041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention Awareness Groups (PAG)
Study NCT02173041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study NCT03931733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Single thirty minute receptive music therapy intervention.
Study NCT01026142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 po twice daily for 14 days every 3 weeks
Study NCT01026142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 mg/m2 po twice daily for 14 days every 3 weeks
Study NCT01026142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg iv loading, then 420 mg iv every 3 weeks
Study NCT01026142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
Study NCT01026142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
Study NCT04151953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for markers of myocardial injury
Study NCT01829425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic medications
Description: The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
Study NCT01829425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
Study NCT04178967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study NCT04178967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT04178967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT01554735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Description: 24 weeks of exercise and diet counselling
Study NCT04078165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-Gravity
Description: Free-floating, suspended personal radiation protection
Study NCT04078165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation protection
Description: Standard lead shields and aprons
Study NCT04608669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Give paracetamol or placebo and compare temperature
Study NCT04608669 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: Give paracetamol or placebo and compare temperature
Study NCT01261754 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1404
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
Study NCT01261754 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 99mTc MIP 1405
Description: Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
Study NCT01549366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Spinous Process Fixation Device
Description: The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
Study NCT01549366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screws
Description: Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
Study NCT02927743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: evidence-based online feedback
Description: GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
Study NCT01106027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
Study NCT03715309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
Study NCT04242160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Clamshell Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
Study NCT04242160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Clamshell Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
Study NCT04242160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Left Anterolateral Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
Study NCT04242160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Anterolateral Thoracotomy
Description: Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
Study NCT01294683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT01294683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
Study NCT01294683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release (ER) niacin/laropiprant (N/LRPT)
Study NCT01294683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01423253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Study NCT03067155 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-specific T cells
Study NCT03067155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anti-viral therapy
Description: Continue with the anti-viral treatment as per standard of care.
Study NCT02512198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription Data Feedback to GP Practices
Description: GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
Study NCT01372670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID
Study NCT01372670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyzine HCL
Description: hydroxyzine HCL dosed on weight given 3x per day
Study NCT01372670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times per day
Study NCT02696772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy intake
Study NCT03354741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laser therapy
Description: stimulation of the acupuncture point P6 by laser therapy
Study NCT02022319 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasonographic Shear Wave Elastography
Study NCT01051700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: Investigational product
Study NCT01051700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01774084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: PreOp, NutriciaNordica AB
Study NCT01774084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Water
Study NCT01504750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic daylight and atmosphere lighting
Description: In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
Study NCT04212988 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Increase the SCO2 value
Description: The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
Study NCT04212988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increase the SCO2 value
Description: The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
Study NCT01524341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 was supplied as capsules for oral use.
Study NCT00568321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624
Description: 50 mcg/kg
Study NCT00568321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN624
Description: 200 mcg/kg
Study NCT00568321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01704963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
Study NCT02437734 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
Study NCT01898689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Description: A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
Study NCT01898689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1%
Description: A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
Study NCT01898689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.4%
Description: A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
Study NCT01898689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.4%
Description: A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab